1. Home
  2. GNFT vs IMA Comparison

GNFT vs IMA Comparison

Compare GNFT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNFT
  • IMA
  • Stock Information
  • Founded
  • GNFT 1999
  • IMA 2019
  • Country
  • GNFT France
  • IMA United States
  • Employees
  • GNFT N/A
  • IMA N/A
  • Industry
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • IMA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GNFT Health Care
  • IMA Health Care
  • Exchange
  • GNFT Nasdaq
  • IMA Nasdaq
  • Market Cap
  • GNFT 186.3M
  • IMA 159.1M
  • IPO Year
  • GNFT 2019
  • IMA N/A
  • Fundamental
  • Price
  • GNFT $3.94
  • IMA $7.96
  • Analyst Decision
  • GNFT Strong Buy
  • IMA
  • Analyst Count
  • GNFT 2
  • IMA 0
  • Target Price
  • GNFT $11.00
  • IMA N/A
  • AVG Volume (30 Days)
  • GNFT 3.9K
  • IMA 34.4K
  • Earning Date
  • GNFT 09-22-2025
  • IMA 01-01-0001
  • Dividend Yield
  • GNFT N/A
  • IMA N/A
  • EPS Growth
  • GNFT N/A
  • IMA N/A
  • EPS
  • GNFT 0.03
  • IMA N/A
  • Revenue
  • GNFT $73,187,701.00
  • IMA $4,300,000.00
  • Revenue This Year
  • GNFT $5.15
  • IMA N/A
  • Revenue Next Year
  • GNFT N/A
  • IMA N/A
  • P/E Ratio
  • GNFT $129.03
  • IMA N/A
  • Revenue Growth
  • GNFT 105.01
  • IMA N/A
  • 52 Week Low
  • GNFT $2.55
  • IMA $7.95
  • 52 Week High
  • GNFT $6.42
  • IMA $23.28
  • Technical
  • Relative Strength Index (RSI)
  • GNFT 47.31
  • IMA N/A
  • Support Level
  • GNFT $3.84
  • IMA N/A
  • Resistance Level
  • GNFT $4.40
  • IMA N/A
  • Average True Range (ATR)
  • GNFT 0.12
  • IMA 0.00
  • MACD
  • GNFT -0.04
  • IMA 0.00
  • Stochastic Oscillator
  • GNFT 12.48
  • IMA 0.00

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

About IMA ImageneBio Inc. Common Stock

ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Share on Social Networks: